Recruiting

Immune Response

Sponsor:

UCLA

Code:

NCT00368615

Conditions

Melanoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The aim of this study is to study T-cells. Blood will be collected and the samples will be used to generate T cell clones. Two separate blood draws will be required at the maximum.

Conditions

Melanoma

Study ID

NCT00368615

Start date

Aug, 2007

Status verified date

Jan, 2024

Completion date

Aug, 2024

Anticipated

Primary completion date

Aug, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Biopsy diagnosis of malignant melanoma
  • Have had a biopsy diagnosis of malignant melanoma in the past

Exclusion Criteria:

  • Patients taking immunosuppressive medications

Study Design

Enrollment

20 participants

Anticipated

Interventions and Outcome Measures

Arms

1

Subjects ages 18-85 years old with biopsy proven melanoma. Peripheral blood will be collected from adults ages 18-85 years old. These samples will then be used for PCR analysis and to generate melanoma-specific T cell clones. If the participant requires a palliative resection of a melanoma tumor(s) then tissue from the tumor will be used to characterize the melanoma's interaction with the immune system and to generate melanoma-specific cell lines. T cell clones isolated from participant's peripheral blood will then be assayed for in-vitro responsiveness to these cell lines. All experiments will be conducted in-vitro.

2

Age-matched controls (no evidence of melanoma)

Primary outcome measure

  • melanoma - peripheral blood [ Time Frame: 2 Years ]

Central Contacts and Locations

Central contacts

Locations

University of California, Davis Department of Dermatology

Recruiting

Sacramento, California, United States, 95816

Contacts

Principal Investigator:

Emanual Maverakis, M.D.

More Information

Sponsor

University of California, Davis

Last update posted

Jan 23, 2024

Last verified

Jan, 2024

Keywords

  • melanoma
  • malignant melanoma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, Davis on 2024-01-23.